Abeona Therapeutics Inc.

Good morning, everyone, and welcome to Abiona Therapeutics 3Q2026 conference call. At this time, all participants have been placed on a listen-only mode, and a question and answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please press star zero on your telephone keypad. Please note this conference is being recorded. I will now turn the conference over to your host, Vice President of Investor Relations and Corporate Communications. Greg, the floor is yours.

Thank you, Tom. Good morning, and thank you for joining us on our third quarter 2026 results conference call.

During this call, we will refer to the press release issued this morning announcing the acquisition of APT 1011 and our third quarter financial results. They're available on our corporate website at www.abmtherapeutics.com. Joining me on today's call are Dr. Vish Seshadri, Chief Executive Officer, Dr. Madhav Vasanthavada, Chief Commercial Officer, Joe Vazzano, Chief Financial Officer, as well as Dr. Brian Kevany, Chief Technical Officer. We will be making projections and forward-looking statements during today's call, which are made pursuant to the safe harbor provisions of the federal securities laws. These forward-looking statements are based on current expectations and our subject's change. Actual results may differ materially from those expressed or implied in the 401 statements due to various factors, including but not limited to those outlined in our Form 10-K and periodic reports filed with the SEC.